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Abstract
Safe and effective immunologic adjuvants are often essential for vaccines. However, the choice of adjuvant for licensed
vaccines is limited, especially for those that are administered intradermally. We show that non-tissue damaging, near-
infrared (NIR) laser light given in short exposures to small areas of skin, without the use of additional chemical or biological
agents, significantly increases immune responses to intradermal influenza vaccination without augmenting IgE. The NIR
laser-adjuvanted vaccine confers increased protection in a murine influenza lethal challenge model as compared to
unadjuvanted vaccine. We show that NIR laser treatment induces the expression of specific chemokines in the skin resulting
in recruitment and activation of dendritic cells and is safe to use in both mice and humans. The NIR laser adjuvant
technology provides a novel, safe, low-cost, simple-to-use, potentially broadly applicable and clinically feasible approach to
enhancing vaccine efficacy as an alternative to chemical and biological adjuvants.
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Introduction
Safe and potent immunologic adjuvants are a key element of
current vaccine design [1,2]. While vaccination is considered
effective as the primary strategy for the control of influenza
infection [3–5], current influenza vaccines without adjuvant are
efficacious in approximately 60% of patients [4,6]. Importantly,
efficacy is reduced in elderly and neonatal populations, where
influenza-related complications and death is much higher than in
other age groups [4,7,8]. Use of immunologic adjuvants in
conjunction with influenza vaccines results in the increased
generation of protective immunity, especially against emerging
viruses with novel hemagglutinin (HA) sequences including H5N1
viruses [1,3,5,9–13]. Unfortunately, while many development-
stage adjuvanted vaccine formulations enhance vaccine efficacy,
they also demonstrate significant side effects [14,15]. Few
adjuvanted vaccines are safe enough to merit approval by
regulatory agencies [3,10]. Tellingly, there is a paucity of effective
adjuvants for influenza vaccine; the recent pandemic H1N1
influenza vaccine went through to production and implementation
without an adjuvant [1,5,16,17]. In light of these considerations,
the development of new, safe and effective adjuvants is important
for current and future vaccination programs.
In addition to new adjuvants, a variety of new vaccine delivery
methodologies have been developed seeking to further optimize
vaccine efficacy. This includes intradermal (i.d.) delivery of vaccine
antigens which is proposed to induce superior protective immune
responses in comparison to conventional intramuscular or
subcutaneous delivery, as the dermis and epidermis are enriched
with antigen-presenting cells (APCs) [18–20]. Work over the past
three decades consistently report that i.d. delivery of reduced
quantities of vaccine antigen can induce equivalent immune
responses for vaccines including influenza, hepatitis B and rabies
[18,19]. Accordingly, i.d. delivered influenza vaccines, including
IntanzaH and IDfluH are now employed in more than 40 countries
[21] and Fluzone IntradermalH was approved by the U.S. Food
and Drug Administration (FDA) in 2011 [22]. However, the
efficacy of the present form of i.d. influenza vaccine is comparable
to the conventional vaccine delivered via the intramuscular route
[19,23]. Use of immunologic adjuvants could further increase the
efficacy and dose-sparing potential of i.d. delivery. These potential
benefits remain unrealized as the candidate adjuvants or adjuvants
used in licensed vaccines are too reactogenic locally when
delivered intradermally [19,24]. Consequently, IntanzaH or
Fluzone IntradermalH do not contain adjuvant. Development of
novel adjuvants designed for i.d. vaccines would therefore
constitute a significant advance.
Previous work using visible range laser light illumination of the
skin report enhanced immune responses to vaccination in humans
and mice [24–26] and could be used as an immunologic adjuvant
for i.d. vaccination. However, these lasers require co-administra-
tion of chemical adjuvant to achieve an effective immunological
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response [24]. In addition, laser light in the green or yellow
spectrums is absorbed by melanin, resulting in highly variable light
absorption across different skin phototypes, limiting the clinical
utility of visible spectrum lasers [27]. Here we report that a
continuous wave (CW), near-infrared (NIR) laser represents a new
class of adjuvant that elicits a robust immune response without the
use of other adjuvant agents independent of skin-phototype. In
concert with i.d. vaccination, NIR laser adjuvants offer a feasible
alternative to chemical adjuvants.
Materials and Methods
Animals
Seven-week-old female C57BL/6J mice were purchased from
Jackson Laboratory. CD11c-eYFP mice were donated by Dr.
Nussenzweig at Rockefeller University. All measurements were
performed in a blinded manner, (to control or experimental
groups).
Laser illumination
We used a neodymium-doped yttrium orthvanadate (Nd:YVO4)
laser (RMI Laser, Lafayette, CO). The 1064 nm laser can be set to
emit either continuous wave (CW) output or nanosecond-duration
pulses (PW) at a periodicity of 10 kHz, while at 532 nm the output
is only PW. Average output powers were determined using a
power meter for each illumination (Thorlabs). The beam profile
for all exposures was flat, with a less than 50% variation in beam
intensity from center to edge. The laser diameter on the skin was
measured approximately 5 mm (0.2 cm2). Mice were depilated
using a hair remover (Nair, Church & Dwight). The following day,
the shaved skin of anesthetized mice was illuminated with the laser
on 4 spots for ovalbumin (OVA) and 1 spot for influenza studies.
The skin temperature was measured during the procedure using
an infrared thermal imager (FLIR Systems).
Skin damage study
For visual inspection, we observed for any signs of skin damage
including blistering, bruising, crusting, edema, redness or swelling
during and at 0, 1, 2, and 4 days after laser illumination. For skin
histology, mice were heart-perfused with 4% paraformaldehyde
before, or at 3, 6, 24, 48, and 96 hours after laser illumination.
Five mm-thick paraffin sections were H & E stained and examined
for microscopic tissue damage, and polymorphonuclear infiltration
were quantitated on the slides in 5 randomized fields using Image J
freeware (NIH).
OVA immunization
Mice were injected intradermally (i.d.) using a 28 G insulin
grade syringe (Kendal) with chromatographically purified OVA
(10 mg in 10 mL saline per spot, 4 spots, Worthington), which was
found to contain less than 1.75 EU/mg of endotoxin using the
Limulus amebocyte lysate QCL-1000 (Cambrex). I.d. delivered
alum- (ImjectH, Thermo-Fisher) adjuvanted OVA, prepared per
manufacturer’s instructions, served as positive control. A dose of
5 mL of ImjectH (200 mg aluminum hydroxide plus 200 mg
magnesium hydroxide) was used per spot. Blood samples were
drawn at 3, 6 and 12 weeks post-vaccination via retro-orbital
bleeding.
Influenza immunization
Mice were injected i.d. with whole inactivated influenza virus
A/PR/8/34 (H1N1) (1 mg in 10 mL saline, 1 spot, Charles River).
Alum-adjuvanted vaccine served as a positive control. Blood
samples were taken 28 days after immunization and 4 days post-
challenge with an intranasal application of live influenza virus 4
weeks after vaccination as previously performed in the context of
i.d. influenza vaccination [28–31].
ELISAs for quantitating anti-OVA and anti-influenza
antibodies
ImmulonTM 2 HB Flat Bottom Plates (Thermo-Fisher) were
coated overnight with 1 mg of OVA at a concentration of 5 mg/
mL or 0.2 mg of inactivated influenza virus at 1 mg/mL. Serially
diluted mouse serum samples were added to the wells and
incubated for 1 hour after the plates were blocked. Bound
immunoglobulins were detected with the appropriate horseradish
peroxidase-conjugated secondary antibody (goat antibody to
mouse IgG [1:10,000, Sigma-Aldrich]; rat antibody to mouse
IgG1 [1:4,000, SouthernBiotech]; rat antibody to mouse IgG2b
[1:500, SouthernBiotech]; goat antibody to mouse IgG2c [1:4,000,
SouthernBiotech]; goat antibody to mouse IgA [1:1,000, Sigma-
Aldrich]; rat antibody to mouse IgE [1:1,000, SouthernBiotech]).
In the case of IgE, the wells were further treated with ELAST
ELISA Amplification System (Perkin Elmer) to improve sensitivity
of the assay. At the end of the incubation, TMB substrate (1-Step
Ultra TMB, Thermo-Fisher) was added and the reaction was
stopped with 2 N sulfuric acid. The reproducibility of the assay
was ascertained by applying mouse anti-ovalbumin IgG (Sigma-
Aldrich) or a hyperimmune mouse serum to influenza to each
plate. We measured the absorption at 450 nm using an ELISA
reader (TECAN SunriseTM plate reader, TECAN). For antibody
titers to OVA and IgE antibody to influenza, a statistically defined
endpoint antibody titer was determined with a confidence level of
99% as previously described [32]. For antibody titers to influenza
except IgE isotype, a titer was designated as a serum dilution
corresponding to an inflection point.
Hemagglutination inhibition (HAI) titration
Mouse sera were analyzed for HAI titers by Charles River
Avian Vaccine Services as described previously [33,34].
Influenza virus challenge study
Mice were anesthetized and challenged intra-nasally with live
influenza A/PR/8/34 at a dose of 1.56106 50% egg infectious
doses (EID50), which is equivalent to 3610
3 50% mouse lethal
dose (MLD50), in 30 mL saline 28 days after vaccination. Survival
and body weight were monitored for 14 days post-challenge. Mice
showing a hunched posture, ruffled fur, or greater than 20% body
weight loss, or mice which were not eating or drinking, were
considered to have reached the experimental end point and were
euthanized [33,34]. MLD50 titers were determined by inoculating
groups of 10 mice intranasally with serial 10-fold dilutions of virus
using the Reed-Muench formula as previously described [33,34].
Influenza virus titration in lung homogenate
Four days after the virus challenge, both sides of the lung were
isolated and homogenized. The EID50 m/L values were deter-
mined by serial titration of the lung homogenate in eggs by
Charles River Avian Vaccine Services as described previously
[33,34].
Splenocyte stimulation and intracellular cytokine staining
Splenocytes were harvested 4 days after the virus challenge as
previously performed in the context of i.d. influenza vaccination
[28–31]. The 26106 splenocytes were re-suspended in 100 ml of
media and incubated for 5 hours in the presence of an inhibitor of
Golgi function (Golgi plug, BD Bioscience) and 1 mg/mL of
Near-Infrared Laser as a Vaccine Adjuvant
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influenza A MHC class I (NP366–374, ASNENMETM, Anaspec),
or II peptides (NP311–325, QVYSLIRPNENPAHK). Multi-param-
eter surface staining for CD3e, CD4, and CD8a (CD3e: 145-
2C11; CD4: RM4-5; CD8a: 53-6.7, BD) was performed, followed
by fixation, permeabilization in Cytofix/CytopermTM (BD Bio-
science) according to the manufacturer’s instructions and intra-
cellular staining for IFN-c, IL-17A, IL-5 (IFN-c: XMG1.2; IL-
17A: TC11-18H10; IL-5: TRFK5, BD). Cell subpopulations,
including influenza-specific IFN-c, IL-17A, IL-5 producing
CD3+CD4+T-helper cells and CD3+CD8+T-cytotoxic cells, were
quantified as a percentage of total viable cells by flow cytometry
using a BD 4 Laser LSR II (BD). Analysis was completed using
FlowJo software (Tree Star).
Quantitation of dendritic cell migration and function in
vivo
Mice were injected with OVA labeled with Alexa Fluor 647
(OVA647, 10 mg in 10 ml saline per spot, 4 spots in total,
Invitrogen) with or without laser illumination. 24 hours after
vaccination, skin-draining lymph nodes (dLNs) were harvested,
minced, and stained for the cell surface and maturation markers
CD11c, CD86, CD80, CD40, and I-Ab (CD86: GL1; CD80: 16-
10A1; I-Ab: AF6-120.1; BD, CD40: 1C10; CD11c: N418,
eBioscience). We then performed flow cytometry on CD11c-
positive dendritic cells (DCs).
To examine temporal and spatial expression of CCL2 and
CCL20, and to quantify DCs in laser-treated skin, we performed
immunofluorescence and confocal microscopic analysis of laser-
treated skin from CD11c-eYFP mice, in which DCs are intravitally
labeled [35,36]. Control animals received sham treatments in
which they were anesthetized and shaved, but not treated with the
laser. Mice were heart-perfused with 4% paraformaldehyde in
PBS via the left ventricle before, or at 6 or 24 hours after 1 minute
of CW 1064 nm laser treatment. The skin was then harvested and
embedded in OCT compound (Tissue-Tek, Sakura). The primary
antibodies used were rat anti-mouse CCL2 (1:50, R&D Systems)
or rat anti-mouse CCL20 (1:10, R&D Systems). Goat anti-rat IgG
(Dylight 549, 1:200, Jackson Immunoresearch) was the secondary
antibody used. 10 mm sections were washed and incubated with
the respective primary antibody overnight at 4uC followed by a
wash and 1 hour incubation at room temperature with the
secondary antibody. Appropriate negative controls were prepared
by omission of the primary antibody. Following application of the
secondary antibody, tissues were washed, counterstained with To-
Pro-3 (1:5000, Invitrogen) and mounted. Digital images of
immunofluorescence slides were obtained by means of confocal
microscopy (Carl Zeiss LSM5 Pascal; Carl Zeiss, Inc.). YFP-
positive DCs were manually counted in 5 randomized fields using
Image J 1.43 freeware (NIH).
Quantitative PCR analysis
Skin sections measuring 565 mm2 and including both the
epidermis and dermis were excised 6 hours after laser illumina-
tion. Total RNA was extracted using the RNeasy Fibrous Tissue
Mini Kit (Qiagen) and reverse-transcribed using the RT2 First
Strand Kit (Qiagen). The samples were tested on an RT2
ProfilerTM PCR Array System (Qiagen) on an Mx3005TM
Multiplex Quantitative PCR System (Stratagene). The fold change
in mRNA expression over sham-treated controls was normalized
against housekeeping genes and calculated following the 2–DDCT
method.
Safety study of NIR laser exposure in humans
We performed an open-label, single-center, single-arm study in
healthy adults. We used a clinically-approved Q-YAG 5 laser
emitting light at 1064 nm (Palomar). The laser was altered to
operate at an average power level below 2 W with an exposure
area of 0.5 cm2, pulse duration of 3 nanoseconds, and pulse
frequency of 10 Hz. We selected qualified subjects with either skin
phototype V or VI [37]. We exposed each subject to a range of
doses by increasing the average irradiance level of each exposure
from 0.5 to 3.7 W/cm2 in stepwise increments of about 0.2–
0.4 W/cm2 each for up to 120 seconds. While subjects were asked
to immediately report any sensations during and after the
exposure, the operator recorded any signs of visible skin damage.
An individual test exposure was stopped if there were any
indications of the subject’s discomfort, pain, or distress, or if the
investigator noted any signs of skin damage. At the end of the
exposure, the operator acquired a digital photograph of the area
and scored the skin sensations and damage. Subjects returned 2
days later for follow-up assessments of their skin conditions and an
additional digital photograph of the area. Subjects came in after 2
weeks if the subject indicated any appearance of skin markings in
the area of the laser exposure.
Ethics Statement
All animal procedures were performed following the Public
Health Service Policy on Humane Care of Laboratory Animals
and approved by the Institutional Animal Care and Use
Committee of Massachusetts General Hospital. The laser safety
study in humans was performed in full conformity with the
Declaration of Helsinki, the current International Conference for
Harmonisation Good Clinical Practice (ICH-GCP) regulations
and all applicable regulatory and ethical requirements. The study
was approved by New England Institutional Review Board
(NEIRB) and the registry number is #09-325. All subjects
provided written informed consent before study-related proce-
dures were performed.
Statistical analysis
We used the Mann Whitney U-test for the comparison of
numerical values between 2 groups, and the Kruskal-Wallis
followed by the Dunn’s test for comparisons of more than three
groups for all statistical analyses unless otherwise specified. Data
were pooled from at least two independent experiments.
Results
Delineation of non-tissue damaging dosages of NIR laser
parameters
We first sought to establish the maximum non-tissue damaging
dosages for the near-infrared (NIR) laser for both continuous wave
(CW) and nanosecond-duration pulse wave (PW) mode as well as
the previously described PW visible lasers [25,26]. Mice received
exposures at escalating irradiances (0.5 to 1.5 W/cm2 for PW
532 nm laser; 0.5 to 6.0 W/cm2 for CW or PW 1064 nm lasers)
for durations up to 4 minutes. Skin damage was evaluated after
illumination by visual inspection and histology. Maximum safe
irradiances were considered to be those at which skin temperatures
did not exceed 43uC and for which no visible or microscopic skin
damage was apparent at any of the post-exposure evaluation times
[27,38]. We identified 1.0 W/cm2 as the maximum safe irradiance
for the PW 532 nm laser (Figure 1A) and 5.0 W/cm2 for both the
1064 nm PW (Figure 1B) and CW lasers (Figure 1C). No visual
damage such blistering, bruising, crusting, edema, redness or
swelling damage was seen when the laser power was below the safe
Near-Infrared Laser as a Vaccine Adjuvant
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irradiance for each parameter for the PW 532 nm laser (Figure
S1A) and 5.0 W/cm2 for both the 1064 nm PW (Figure S1A) and
CW lasers (Figure 1D). On a histological examination, no tissue
damage or inflammatory response at any given time point was
detected by H & E staining (Figure 1E) with minimal polymor-
phonuclear cell-infiltration in the skin after the administration of
5.0 W/cm2 of CW 1064 nm laser (Figure 1F). Thus, we concluded
that the dosages below 1.0 W/cm2 for the PW 532 nm and
5.0 W/cm2 for both the 1064 nm PW and CW lasers are non-
tissue damaging and non-inflammatory.
Safety and tolerability of the non-tissue damaging
dosage of NIR laser in humans
In order to determine if the NIR laser dose used in mice is safe
and tolerable in humans, we performed a clinical study (Figure 2A).
Five subjects with skin phototypes V or VI were enrolled [37], and
each subject received 16 exposures of a clinically-approved
1064 nm laser at escalating irradiances (0.5 to 3.7 W/cm2) for
durations up to 2 minutes each (Table 1). All subjects tolerated the
highest irradiance for 2 minutes (total dose 442 J/cm2) with no
subject reporting severe skin sensations or distress (Table 2).
Investigators noted no significant skin damage during any laser
exposure (Figure 2B–D). Laser-induced skin damage is a function
of skin heating, which depends upon the duration of exposure,
wavelength and irradiance [38]. With the same wavelength and a
similar order of irradiance and the duration of exposure, the heat
generation in the animal and human studies is equivalent. Thus,
we conclude that a NIR laser at equivalent irradiances and doses
used in mice is safe and well tolerated in humans.
NIR laser adjuvant enhances antibody response to a
model vaccine
We next tested whether NIR laser treatment at safe irradiances
and doses could enhance immune responses to vaccination in mice
as compared to the licensed adjuvant, alum. First, mice received 1-
or 4-minute exposures to CW or PW 1064 nm or PW 532 nm
lasers on the back skin. Immediately thereafter, mice received an
i.d. injection of OVA. Alum-adjuvanted OVA i.d. served as
positive controls as i.d. injection of alum has been used to increase
the efficacy of vaccines both in mice [39–42] and humans [43,44].
Notably, the 1-minute CW 1064 nm laser treatment induced the
highest antibody titer among all the tested parameters, which were
significantly higher at all time points than both the non-adjuvanted
controls (Figure 3A, 3 weeks: P,0.01; 6 weeks: P,0.05, 12 weeks:
P,0.05). The anti-OVA specific IgG antibody titer in the
previously explored 4-minute PW 532 nm laser-treated group
was not significantly higher than those in non-adjuvanted controls
at any time point (Figure 3A). There is no significant difference
between CW 1064 nm laser-treated and alum-adjuvanted groups
at any time point (Figure 3A). We did not find a relationship
between maximal skin surface temperature during laser treatment
and antibody titer (Figure 3B), suggesting that heat generation as a
result of laser exposure does not play a significant role in
enhancing immune responses. We selected the 1-minute CW
Figure 1. Effect of laser on skin tissue. A–C, Dose-temperature responses of the PW 532 nm laser and the PW and CW 1064 nm laser in mouse
skin. n=1–4 (4–16 exposures in total) for each group. PW, pulse wave; CW, continuous wave; Tm, maximal skin surface temperature. Error bars show
means 6 s.e.m. D, Images of the back of mice for visual inspection at 0 and 24 hours after the CW 1064 nm NIR laser treatment. Representative
images for each group are presented. A–D, n= 1–4 (4–16 exposures in total) for each group. E, Microscopic assessment of skin damage and
inflammatory infiltration after laser treatment. Representative time-course images of hematoxylin-eosin-stained skin tissue are presented. The bar
indicates 50 mm. F, Quantification of polymorphonuclear leukocytes (PMN) after the NIR laser treatment. E–F, n= 3 for each group.
doi:10.1371/journal.pone.0082899.g001
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1064 nm laser exposure as the most effective and efficient immune
adjuvant for subsequent experiments.
NIR laser adjuvant induces functional changes in DCs
Previous studies indicate that licensed and experimental
immunologic adjuvants activate DC-mediated innate immune
responses resulting in robust adaptive immune responses [3,10,45–
47]. To investigate if the NIR impacts DC trafficking and
function, we injected fluorescently labeled OVA i.d. into mice and
assessed both OVA-positive DCs in skin-dLNs and their activation
status. The NIR laser treatment induced an up-regulation of
maturation markers including MHC class-II, CD40, and CD86
compared to controls injected i.d. with OVA only (Figure 4A–C,
MHC II: P = 0.013; CD40: P = 0.010: CD86: P,0.037), but did
not increase CD80 expression or OVA-positive DC populations
above those of the controls (Figure 4D and 4E). To further
determine the impact of NIR laser exposure on DC trafficking in
the skin, we treated the skin of CD11c-YFP transgenic mice, in
which DCs are intravitally labeled [35,36], with a 1-minute
exposure of the CW 1064 nm laser. We observed an over 2-fold
increase in the concentration of DCs in both the epidermal and
dermal areas of exposure, reaching a maximum 6 hours after
treatment (Figure 5A and 5B, no laser control vs. laser treated in
epidermis: 5896125 vs. 1,0456113/mm2, P = 0.038; dermis:
195636 vs. 415662/mm2, P = 0.040), and returning to the
baseline level of non-treated skin by 24 hours. These data suggest
that key mechanistic elements for the NIR laser include
migrational and functional changes of DCs in skin and draining
lymph node.
NIR laser adjuvant results in the transient expression of a
defined set of chemokines
After establishing the beneficial effect of NIR laser upon DCs,
we sought to identify the mechanisms contributing to the
migration and activation of DCs by the NIR laser. Skin cells
function as sentinels for damage or pathogen invasion by releasing
Figure 2. NIR laser safety study in humans. A, Schedule of laser treatment and follow-up skin appearance documentation. Five healthy adults
aged 20 to 46 years old with either skin phototype V or VI were enrolled. B, A plastic grid was used to separate the laser exposure sites. An aqueous
gel was applied in each section of the grid to enhance the dissipation of heat from the skin’s surface. The bar indicates 1 inch. C and D, Representative
images of the laser-exposed skin are shown at (C) 1 hour and (D) 2 days after completion of the treatment. No detectable skin damage on visual
inspection was observed following laser exposure at any irradiance used.
doi:10.1371/journal.pone.0082899.g002
Table 1. List of enrolled subjects and tolerated doses.
Patient number Age Gender Skin phototype
Tolerated irradiances
(W/cm2)
Maximum tolerated
fluences (J/cm2)
Premature termination
of the laser exposure
1 24 F V 0.5–3.7 441.6 No
2 21 F V 0.5–3.7 441.6 No
3 46 F VI 0.5–3.7 441.6 No
4 34 F V 0.5–3.7 441.6 No
5 20 F V 0.5–3.7 441.6 No
Study subjects were screened for inclusion and exclusion criteria detailed in Materials and Methods. Subjects were selected with either skin phototype V or VI because,
at 1064 nm, levels of laser power and exposure time that proved to be non-painful and non-damaging in subjects with the darkest skin types would be predicted to be
non-painful and non-damaging for all other skin types.
doi:10.1371/journal.pone.0082899.t001
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pro-inflammatory cytokines to recruit and condition APCs
including DCs [45]. We therefore tested the effect of NIR laser
upon chemokine production and signaling. We measured the
expression of 160 genes related to inflammatory cytokines, their
receptors, and inflammasomes using qPCR, 6 hours after the 1-
minute CW 1064 nm laser treatment, Gene expression for a
selective set of cytokines, including Ccl2 and Ccl20, increased
significantly (Figure 5C and Table S1). CCL2 and CCL20 protein
expression has been shown to be involved in DC migration and
recruitment [48]. 6 hours after the laser treatment, CCL2 was
expressed in the epidermal and dermal regions, possibly in
keratinocytes, fibroblasts and mast cells (Figure 5D, top row).
CCL20 was expressed sporadically in the dermis, possibly in mast
cells (Figure 5D, middle row). The expression of both CCL2 and
CCL20 declined at 24 hours, matching the timing of DC
localization to the laser-treated skin. Taken together, these data
indicate that the NIR laser adjuvant stimulates the expression of a
defined set of cytokines and chemokines which collectively could
induce functional and migrational changes in DCs in the skin.
The NIR laser adjuvant enhances humoral immunity
without inducing an IgE response
We next examined the adjuvant effect of visible and NIR lasers
in a murine influenza vaccination and lethal challenge model and
compared them with alum. Mice received a single laser dose and
were injected i.d. with whole inactivated influenza virus A/PR/8/
34. We also used alum-adjuvanted vaccine to examine whether the
laser adjuvant can induce responses comparable to a licensed
chemical adjuvant, as i.d. injection of alum has been used to
increase the efficacy of vaccines both in mice [39–42] and humans
[43,44]. The CW 1064 nm laser significantly augmented pre-
challenge IgG and IgG1 titers compared to the non-adjuvanted
group (Figure 6A–C, IgG: 1064 nm vs. controls: P = 0.012, IgG1:
1064 nm vs. controls: P = 0.040). Alum also produced elevations in
IgG1 titers that were greater than non-adjuvanted controls
(P,0.0001). The IgG2c responses were similar among all test
groups. Post-challenge, the CW 1064 nm laser significantly
augmented anti-influenza IgG, IgG1 and IgG2c titers compared
to the non-adjuvanted group (Figure 6D–F, IgG: P = 0.001; IgG1:
P = 0.026; IgG2c: P = 0.023). In comparison, the PW 532 nm laser
Table 2. Reported sensations and signs of skin damage on each NIR laser dose.
Subjects Number of sensations Total events
Laser irradiances
(W/cm2) 1 2 3 4 5 Mild Moderate Severe
0.5 0 0 0 0
0.7 0 0 0 0
0.8 0 0 0 0
1.1 0 0 0 0
1.4 1 1 0 0 1
1.5 1,2 1 1 0 2
1.7 0 0 0 0
2.2 4 1 0 0 1
2.5 4 4 2 0 0 2
2.7 4 4 1 3 0 0 3
2.9 1,2 1,2 4 1,2 4 3 0 7
3.1 1,2 1 4 3 1 0 4
3.3 1 4 1,2 3 1 0 4
3.4 1,9 4,9 1 3 0 0 5
3.5 9 4,9 1 1 1,2 4 1 0 7
3.7 2,9 9 1,2 1 1,2,9 3 3 0 9
Consenting human subjects were exposed to a range of laser doses from 0.5 to 3.7 W/cm2 (16 doses) each up to 120 seconds. Sensations felt by subjects were classified
as mild (warmth, tingling, itching, pinprick/needle sensations), moderate (hotness, dull pain), or severe (burning, sharp pain), and recorded. The operator also recorded
any signs of skin damage.
1Warmth
2Hotness
3Burning
4Pinprick/needle sensations
5Dull pain
6Sharp pain
7Tingling
8Itching
9Skin appearance change; No changes in skin appearance or damage were noted on all exposures, except transient skin darkening (transient hyperpigmentation)
occurred in some subjects, which was due to changes in capillary blood flow in the treated area. These changes were not observed during follow-up examination after
2 hours.
10Skin damage
doi:10.1371/journal.pone.0082899.t002
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augmented only IgG and IgG2c titers (IgG: P = 0.028; IgG2c:
P = 0.003), and alum increased only IgG1 titers (P,0.001). The
finding that alum elicited an IgG1-biased response is consistent
with published literature showing that alum induces a profoundly
polarized T helper type 2 (TH2) immune response with
consequently elevated IgE production and hypersensitivity in mice
[3,10,15], a finding replicated in this study (Figure 6G, P,0.0001
compared to the non-adjuvanted group). In contrast, the laser
adjuvants did not increase IgE responses to the vaccine
(Figure 6G). Influenza-specific IgA in the lung homogenate was
not detected in any experimental group (data not shown),
suggesting mucosal IgA does not contribute to protection in this
model. These data indicate that NIR laser treatment produces a
mixed TH1-TH2 immune response to influenza vaccination
without enhancing an IgE response.
NIR laser adjuvant induces a balanced systemic TH1-TH2
cell-mediated immune response
Previous studies suggest that effector CD4+ and CD8+ T cell-
mediated immune responses contribute to protection from
influenza [49,50]. To determine whether the NIR laser elicits
these cell-mediated immune responses, we re-stimulated spleno-
cytes from influenza-challenged mice ex vivo with influenza
peptides and then assessed the expression of cytokines in T-cell
subpopulations. Influenza-specific CD4+IFN-c+ T-cell subpopu-
lations induced by a major histocompatibility complex (MHC)
class-II peptide were significantly increased in the 1064 and
532 nm laser-treated groups compared to non-adjuvanted controls
(Figure 7A, CW 1064 nm laser: P = 0.044; PW 532 nm laser:
P = 0.003). Only the CW 1064 nm laser also significantly
increased influenza-specific CD4+IL-5+ T-cell subpopulations
(Figure 7B, P,0.003). No test groups showed significantly
increased responses of influenza-specific CD4+IL-17+ T-cell
subpopulations to MHC class-II peptide, or CD8+IFN-c+ T-cells
to MHC class-I peptide, compared to the non-adjuvanted controls
(Figure 7C and 7D). These data show the unique ability of the
non-tissue damaging NIR laser to induce a systemic TH1-TH2
immune response to an inactivated influenza vaccine.
NIR laser adjuvant confers equivalent protective
immunity to alum
After determining the quality of the laser-induced immune
response, we sought to test the ability of this strategy to generate a
protective response against lethal influenza virus challenge. Mice
were vacciniated and allowed to rest for four weeks. Subsequently,
naı¨ve and vaccinated mice were challenged intra-nasally with
homologous live influenza virus and monitored for survival time.
In the lethal challenge model, the CW 1064 nm laser-treated
group showed a marked decrease in lung viral titers by a factor of
101.9 compared to the non-adjuvanted group at 4 days after
challenge (Figure 8A, P = 0.025), while the PW 532 nm laser-
treated group failed to show any significant impact. In addition,
the single one minute duration CW 1064 nm laser treatment
consistently conferred better protective immunity while the PW
532 nm laser treatment did not, as determined by survival time
after viral challenge (Figure 8B, P = 0.036). Body weight loss upon
viral challenge in CW 1064 nm laser-treated group was smaller
than in PW 532 nm laser-treated group (Figure S2). There was no
significant difference in protection and body weight loss between
CW 1064 nm laser-treated and alum-adjuvanted groups. Consis-
tent with protection and antibody levels, clinically relevant HAI
titer levels in the CW 1064 nm laser group were higher than in the
non-adjuvanted, 532 nm laser-treated and alum-adjuvanted
groups in pre-challenge serum (Figure 8C), and higher than the
non-adjuvanted group and comparable to those in the alum-
adjuvanted group in post-challenge serum (Figure 8D). These data
support the view that NIR laser induces protective immune
responses to an inactivated influenza vaccine.
Discussion
We have shown, for the first time, that non-tissue damaging
NIR laser light given in short exposures to small areas of the skin,
without the use of any additional agents, increases a broad
Figure 3. Effect of laser on the humoral immune response to a model vaccine. A, Serum ovalbumin- (OVA)-specific IgG titers 3, 6, and 12
weeks following vaccination with 40 mg OVA with or without laser illumination. Endpoint titer of OVA-specific serum IgG was determined by ELISA.
Plates were coated with OVA. n=33, 19, 15, 12 and 11, 5 and 6, 6 and 6 for no OVA, OVA i.d., OVA +Alum i.d., OVA i.d. + PW 532 nm 1 and 4 minutes,
OVA i.d. + PW 1064 nm 1 and 4 minutes, OVA i.d. + CW 1064 nm 1 and 4 minutes, respectively. Error bars show means 6 s.e.m. *P,0.05, **P,0.01
and ***P,0.001 as compared to OVA i.d. B, The relationships between anti-OVA antibody titers following 1–4 minutes PW 532 nm, PW 1064 nm and
CW 1064 nm laser-treated groups at 6 weeks (logIgG) and maximal skin surface temperature (Tm) was not statistically significant; a Pearson’s
correlation coefficient r=20.237 (P= 0.08), where log(IgG) =20.193Tm+10.75 (linear regression, R2 = 0.056). n= 20, 17, 18, for OVA i.d. + PW 532 nm
1–4 minutes, OVA i.d. + PW 1064 nm 1–4 minutes, OVA i.d. + CW 1064 nm 1–4 minutes.
doi:10.1371/journal.pone.0082899.g003
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Figure 4. Effect of the near-infrared (NIR) laser adjuvant on the function of dendritic cells (DCs). A–E, Quantitation of DC activation
markers (A) MHC class-II, (B) CD40, (C) CD86 and (D) CD80, and (E) the number of CD11c+OVA647+ DCs in skin-draining lymph nodes 24 hours after
vaccination with 40 mg Alexa Fluor-647-labeled OVA (OVA647) with or without the 1-minute CW 1064 nm NIR laser treatment. Data are the ratio of
median fluorescence intensity (MFI) of each marker normalized to no OVA controls. n= 7, 9, 15 for no OVA, OVA647 i.d., and OVA647 i.d. + CW 1064 nm,
respectively; ANOVA with Bonferroni correction. AU, arbitorary units. A–E, Data are derived from at least three independent experiments.
doi:10.1371/journal.pone.0082899.g004
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spectrum of immune responses to influenza antigen. This occurs at
a magnitude comparable to a licensed adjuvant, and results in
improved survival in a lethal challenge murine model. NIR lasers
have been used at high wattages in the field of medicine for
decades [38]. Millions of people have been treated with 1064 nm
lasers for tattoo and hair removal, skin tightening and regeneration
at much higher powers than described in this study. The
irradiances used in the study (in both mice and humans) are 10-
fold less than those used for FDA-approved and safe cosmetic
1064 nm laser applications. The immune adjuvant settings would
therefore be expected to be safer than NIR laser settings for
cosmetic tissue destructive hair follicle and tattoo removal. To our
knowledge, there are only two published reports of adverse effects
related to these applications including a possible allergic response
after Nd:YAG treatment. However, these were delayed type
hypersensitivity reactions against the tattoo ink in the skin [51,52].
Therefore, the finding that the exposure of a small area of skin to
low-wattage NIR laser light is both tolerable and safe in humans
could support rapid approval of this approach by the FDA.
The use of a low-power NIR laser with CW output has several
clear advantages over visible lasers previously explored as
adjuvanting devices [25,26], as well as currently approved
chemical vaccine adjuvants. Since water is the predominant
chromophore for the NIR laser, light absorption is not significantly
altered across different skin phototypes [53]. Further, the laser is
external to a vaccine, avoiding stability issues that complicate
conventional vaccine-chemical adjuvant combinations. Low-watt-
age CW 1064 nm NIR lasers are a mature, safe, compact and
Figure 5. Effect of the near-infrared (NIR) laser adjuvant on the migration of dendritic cells (DCs). A and B, Quantification of CD11c+ DCs
in skin before (n= 6) and at 6 (n=8) and 24 hours (n= 4) after the NIR laser treatment. The number of DCs in the (A) epidermal and (B) dermal
compartments; ANOVA with Bonferroni correction. A–B, Data are derived from at least three independent experiments. C, Relative gene expression of
inflammatory cytokines and chemokines in the skin 6 hours after laser treatment (n=4–5) and in the no laser control mice (n=4) was quantified by
qPCR. *P,0.05 as compared with control mice; Student’s unpaired two-tailed t test. A–C, Error bars show means 6 s.e.m. D, Confocal imaging of
CCL2 expression (red, top row), CCL20 expression (red, middle row), CD11c+ DCs (green) and nuclear counterstaining (To-Pro-3 in blue) in skin before
treatment and at 6 and 24 hours after the NIR laser treatment. Images are representative from three independent experiments. Scale bar, 50 mm.
doi:10.1371/journal.pone.0082899.g005
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Figure 6. Effect of the laser adjuvant on humoral anti-influenza immune responses. A–G, Influenza-specific IgG subclass titers (A–C) in pre-
challenge serum (4 weeks after vaccination) and (D–G) post-challenge (4 days after challenge). Mice were vaccinated with 1 mg of inactivated
influenza virus (A/PR/8/34) with or without laser illumination or the licensed chemical adjuvant (alum) and challenged intranasally with live
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relatively simple technology, making it possible to economically
produce a portable (handheld) low cost device that, at sufficient
vaccination volumes, could offer a feasible alternative to chemical
adjuvants. In addition, the NIR laser adjuvant could be readily
translated into a safe, clinically applicable, approach as NIR laser
devices already approved by the FDA- and European Medicines
Agency- (EMEA-) could perform this function. All of these factors
would reduce the logistical challenges of mass vaccination
campaigns of underserved or outlying populations. Finally, the
NIR laser greatly reduces potential adjuvant reactogenicity and
toxicity, as it neither induces a prolonged inflammatory cytokine
response nor promotes allergenicity, all while not persisting in
exposed tissue. These features of a NIR laser adjuvant stand in
contrast from well recognized drawbacks of chemical adjuvants
[54].
We demonstrated that a single one-minute application of NIR
1064 nm laser alone to the skin, in conjunction with an influenza
vaccine, induced a robust TH1-TH2 balanced and potentially
protective immune response [55–58]. This contrasts with a
nanosecond PW, visible 532 nm laser which induced a TH1-
skewed response with little impact on the IgG1 response.
Furthermore, the NIR laser, given in conjunction with i.d.
influenza vaccine, confers protective immunity that assists in viral
clearance from the lung and abrogates the need for a chemical
adjuvant. In contrast, the visible range 532 nm laser exhibited
minimal capacity to clear the virus and failed to confer protection
in a lethal challenge model. IgA on the mucosal surface and a local
TH1 response play a key role in controlling infections [59–62].
However, IgA was not detected in lungs and a TH1 response was
increased in both CW 1064 and PW 532 nm laser-treated groups
in this model. This suggests that a TH2 response is essential in
conferring protection by the laser adjuvant in the context of i.d.
vaccination using inactivated vaccine as evidenced by the critical
role of IgG1 subclass in protection [56,63]. Comparable protec-
tion with a TH2 response could be obtained by use of licensed or
candidate adjuvants including alum, but these chemical or
biological adjuvants are generally too reactogenic when delivered
by the i.d. route [19,24]. Our data support the view that the NIR
laser adjuvant has the ability to activate immune responses in the
dermis and epidermis, and therefore has the potential to replace
problematic chemical and biological adjuvants.
We show that the mechanisms of action of the NIR laser
adjuvant involve the transient expression of a limited set of
cytokines and chemokines, including CCL2 and CCL20, which
are known to direct recruitment of DCs to laser-illuminated skin
and regulate adaptive immune responses [45,48]. Key mechanistic
elements identified so far include migrational and functional
changes in DCs in both skin and draining lymph nodes. Our
dataset supports this mechanistic action and demonstrates that the
effect on DCs is evident within 6 hours post laser application, and
is associated with augmentation of an adaptive immune response.
Moreover, these immune stimulatory effects are completed within
24 hours after exposure without a residual effect beyond this time
that would be generated by retained chemical or biological
adjuvant material that could stimulate additional adverse effects.
Finally we show that a thermal mechanism, which is known to
enhance immune responses as a result of tissue damage, does not
mediate the efficacy of the NIR laser adjuvant.
The magnitude of a CD4+ T cell response has been shown to be
proportional to the number of DCs as well as their quality when
they reach the lymph node [64]. Although the NIR laser adjuvant
enhances adaptive immune responses, it did not induce a
detectable increase of DCs in skin-draining lymph nodes. The
migration of mature DCs to the draining lymph nodes is regulated
at the multiple steps by expression of chemokines and chemokine
receptors which play a determinant role in the trafficking of DCs
to lymph nodes through afferent lymphatic vessels [64,65]. As
shown in this study, the tissue response to the laser illumination
resulting in expression of chemokines tapers down within
24 hours, which would be long enough to initiate DC migration
and maturation in situ but may not provide DCs with an additional
guidance cue to traffic into lymph nodes.
Both government and non-governmental organizations have
established as long-term objectives the reduction or elimination of
chemical adjuvants when possible, as well as the development of
needleless vaccinations. The NIR laser vaccine adjuvant technol-
ogy, which could be readily incorporated into practice as a low-
cost and easy-to-use handheld device, opens a new pathway
towards achieving the long-term objectives in clinical practice.
When combined with skin-based and needle-free technologies
such as microneedles and transcutaneous immunization (TCI)
patches [18,19,66,67], use of the NIR laser adjuvant could
eliminate the need for any type of hypodermic needle.
In summary, the NIR laser-based adjuvant represents a novel
technology that could offer a feasible alternative for chemical and
biological adjuvants in vaccines while facilitating the use of
intradermal needleless vaccination in the future.
Supporting Information
Figure S1 Non-tissue damaging parameters of the laser
adjuvants. Mice received continuous wave (CW) or nanosecond-
pulsed (PW) 1064 nm or PW 532nm laser illumination on four
areas of shaved and depilated back skin for up to three min.
Surface skin temperature was monitored with an infrared
thermometer. A–B, Images of the back of mice for visual
inspection at 0 and 24 h after laser illumination. There was no
visible damage detected when the irradiance was below 1.0 W/
cm2 for the PW 532 nm laser or 5.0 W/cm2 for the PW 1064 nm
lasers, as evidenced by erythema, tissue edema, or bruising. A–B,
n = 1–4 (4–16 exposures in total) for each group. Representative
images for each group are presented.
(TIF)
Figure S2 Effect of laser illumination on body weight
following viral challenge. Mice were vaccinated intradermally
with 1 mg inactivated influenza virus (A/PR/8/34) with or without
laser illumination, or alum-adjuvant. 28 days later, the mice were
intranasally challenged with homotypic virus. Body weights were
monitored daily for 15 days. Mean body weight 6 s.e.m. of each
experimental group was determined at each time point. n = 16, 20,
13, 21, 11 for no vaccine, vaccine i.d., vaccine i.d. + PW 532 nm,
vaccine i.d. + CW 1064 nm, and vaccine + Alum i.d. vaccine
groups.
(TIF)
Table S1 Effect of the NIR laser illumination on the
cytokine and chemokine expression in the skin. 6 hours
homologous virus 4 weeks after vaccination. Titer of influenza-specific serum IgG subclass was determined by ELISA. Plates were coated with
inactivated influenza virus. (A and D) IgG, (B and E) IgG1, (C and F) IgG2c, and (G) IgE titers. Experimental and control groups: (A–C) n=38, 47, 25, 50,
12 (D–F) n= 25, 29, 12, 32, 12 (G) n= 24, 21, 13, 24, 12 for no vaccine, vaccine i.d., vaccine i.d. + PW 532 nm, vaccine i.d. + CW 1064 nm, and vaccine +
Alum i.d. vaccine groups, respectively.
doi:10.1371/journal.pone.0082899.g006
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after the 1-minute CW 1064 nm laser treatment, the laser-treated
skin sections were excised and total RNA was extracted. We
measured the expression of 160 genes related to inflammatory
cytokines, their receptors and inflammasomes using a RT2
ProfilerTM PCR Array System. The fold change in mRNA
expression over sham-treated controls were normalized against
housekeeping genes and calculated following the 2–DDCT method
per the manufacturer’s instructions.
(DOC)
Figure 7. Effect of the laser adjuvant on cell-mediated anti-influenza immune responses. Systemic CD4+ helper T-cell responses were
measured 4 days after challenge by re-stimulating 26106 splenocytes with a nucleoprotein (NP) major histocompatibility class-II complex (MHC) or
class-I influenza-specific peptide. Percentages of (A) CD4+IFN-c+ (B) CD4+IL-5+ (C) CD4+IL-17+ and (D) CD8+IFN-c+ T cells are shown. Also shown are
representative FACS plots. Error bars show means 6 s.e.m. Experimental and control groups: (A–D) n=16, 18, 13, 20, 10 for no vaccine, vaccine i.d.,
vaccine i.d. + PW 532 nm, vaccine i.d. + CW 1064 nm, and vaccine + Alum i.d. vaccine groups, respectively.
doi:10.1371/journal.pone.0082899.g007
Figure 8. Effect of the laser adjuvant on protective immunity. A, EID50 was determined by serial titration of lung homogenate in eggs at 4
days after challenge. EID50, the 50% egg infectious dose. B, Kaplan-Meier survival plots of influenza-vaccinated mice for 15 days following lethal
challenge; Gehan-Breslow-Wilcoxon test. C, HAI titers (C) in pre-challenge (4 weeks after vaccination) and (D) post-challenge (4 days after challenge)
serum. Experimental and control groups: (A) n=9, 10, 6, 9, 6 (B) n= 16, 20, 13, 21, 11 (C) n= 31, 38, 24, 41, 6 (D) n=23, 31, 13, 34, 12 for no vaccine,
vaccine i.d., vaccine i.d. + PW 532 nm, vaccine i.d. + CW 1064 nm, and vaccine + Alum i.d. vaccine groups, respectively.
doi:10.1371/journal.pone.0082899.g008
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